Codexis vs Standard Biotools
Standard Biotools reported revenue of $85 million in fiscal 2025, 1.2 times Codexis' $70 million in fiscal 2025. Codexis' revenue grew 18.6% in its latest year, and Standard Biotools' fell 6.2%. Codexis had an operating margin of -59.3%, against -129.2% at Standard Biotools. Free cash flow was −$24 million at Codexis and −$83 million at Standard Biotools.
Side by side
| Codexis | Standard Biotools | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $70M | $85M |
| Revenue growth | 18.6% | −6.2% |
| Revenue growth a year, last 5 years | 0.4% | −9.2% |
| Gross margin | 86.7% | 49.9% |
| Operating margin | −59.3% | −129.2% |
| Net margin | −62.5% | −87.8% |
| Free cash flow | −$24M | −$83M |
| Free cash flow margin | −33.9% | −96.8% |
| Return on capital | −189.5% | −41.9% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 18.7% | 8.0% |
| Last close | $1.05 | $0.61 |
| P/E at the last close | — | 1.8× |
| Insider trades, last 12 months | sold $933,396 | bought $11.1 million, sold $0 |
| Piotroski F-score | 4 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CodexisStandard Biotools
Operating margin
Percent of revenue
CodexisStandard Biotools
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CodexisStandard Biotools
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Codexis and Standard Biotools pages.